Johnson & Johnson May Sell Synthes’ Orthopedic Trauma Unit to Appease Regulators

Johnson & Johnson recently made concessions to convince the European Union’s antitrust regulator that it’s acquisition of Swiss company Synthes is clear of any issues, according to a New York Times report.

Advertisement

The company agreed to potentially sell Synthes’ trauma unit to appease regulators. A ruling is expected by April 26 on the $21.3 billion takeover. Boards of both companies approved the acquisition.


Sign up for our FREE Orthopedic E-Weekly for more coverage like this sent to your inbox!

Related Articles on Orthopedic Devices:
Medtronic’s Biologics Business Down 20% in 3Q With Infuse Sales Dropping

DJO Global Finalizes, Expands Partnership With Lima

ArthroCare Revenues Down in 2011

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.